TABLE 2

Model characteristics for mesothelioma discrimination

ResultsComparison
MPM versus HCMPM versus AExMPM versus ARDMPM versus AEx+ARDMPM versus BLDMPM versus LC
Subjects n52 versus 5252 versus 5952 versus 4152 versus 10052 versus 7052 versus 56
Sensitivity %88.5 (77.6–95.2)86.5 (75.2–93.9)88.5 (77.6–95.2)94.2 (85.1–98.5)71.2 (57.8–82.2)73.1 (59.9–83.8)
Specificity %42.3 (29.5–56.0)89.8 (80.1–95.8)73.2 (58.2–85.0)80.0 (71.3–87.0)87.1 (77.8–93.5)71.4 (58.7–82.1)
PPV %60.5 (49.3–71.0)88.2 (77.2–95.1)80.7 (69.0–89.4)71.0 (59.6–80.8)80.4 (67.2–90.0)70.4 (57.3–81.4)
NPV %78.7 (60.7–90.8)88.3 (78.3–94.7)83.3 (68.6–92.9)96.4 (90.5–99.1)80.3 (70.2–88.1)74.1 (61.2–84.4)
Accuracy %65.4 (55.9–74.0)88.3 (81.3–93.3)81.7 (72.9–88.6)84.9 (78.5–89.9)80.3 (72.6–86.7)72.2 (63.3–80.0)
AUCROC#0.612 (0.502–0.724)0.879 (0.799–0.948)0.850 (0.764–0.927)0.890 (0.832–0.942)0.837 (0.759–0.907)0.770 (0.678–0.855)
VOCsP0, P4, P10, P15, P66, P85, P88, P92, P99, P103, P104, P108, P114, P119, P170, P189, P192, P196, P203, P207, P208, P212, P218, P223P1, P3, P7, P9, P15, P21, P22, P26, P65, P66, P73, P75, P84, P99, P101, P110, P112, P114, P118, P120, P126, P132, P133, P137, P176, P177, P184, P186, P195, P210, P212, P221, P223, P225, P229, P231, P237, P243, P244, P248P1, P9, P15, P21, P26, P34, P83, P88, P92, P94, P102, P108, P114, P119, P127, P176, P181, P185, P187, P195, P201, P207, P212, P220P1, P7, P9, P15, P21, P26, P70, P83, P84, P88, P101, P110, P118, P122, P123, P142, P151, P153, P159, P161, P167, P173, P178, P222, P235, P236, P240P1, P8, P9, P15, P42, P98, P115, P121, P123, P130, P131, P137, P164, P220, P237, P243, P245P0, P7, P8, P9, P15, P21, P28, P37, P42, P43, P48, P64, P73, P78, P107, P108, P115, P116, P117, P123, P129, P136, P145, P150, P151, P156, P172, P181, P186, P215, P216, P223, P224, P225, P231, P237, P244

Data are presented with 95% CI in parentheses. AEx: asymptomatic asbestos-exposed controls; ARD: patients with benign asbestos-related diseases; HC: healthy controls; MPM: malignant pleural mesothelioma; BLD: patients with benign non-asbestos-related lung diseases; LC: patients with primary lung cancer; NPV: negative predictive value; PPV: positive predictive value; AUCROC: area under the receiver operator characteristic curve; VOC: volatile organic compound. #: AUCROC significantly different from 0.5; : >50% of times selected (VOCs in bold are selected in >80% of folds).